Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 25Thoracic 11Gastrointestinal 10Lymphoid 8Gynecologic 8CNS 8Head & Neck 7Other solid neoplasm 6Genitourinary 5Other hematologic neoplasm 4Tumor-Agnostic 3Dermatologic 3Sarcoma 2

Conditions

Neoplasm Metastasis 3Neoplasms 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NVP-BKM120 × Tumor-Agnostic × Clear all
NCT01285466 2020-12-09

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

Novartis

Phase 1 Completed
110 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01911325 2018-08-14

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Novartis

Phase 1 Terminated
27 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02035124 2016-02-11

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

SCRI Development Innovations, LLC

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡